Oral squamous cell carcinoma (OSCC) is a prevalent malignancy with poor prognosis, largely attributed to p53 mutations in 65%–85% of cases. Mutant p53 loses tumour-suppressor functions and gains oncogenic roles, promoting cancer progression and therapy resistance. Targeting mutant p53 represents a promising therapeutic avenue.
Aim:
The aim of this study was to evaluate the potential of 4-amino benzoic acid (PABA)-substituted pyrimidine derivatives as novel inhibitors of mutant p53 protein through in silico analyses.
Materials and Methods:
Mutant p53 (PDB ID: 4mzi) was retrieved from the RCSB Protein Data Bank. PABA derivatives (3A, 3B, 3C and 3D) were assessed for drug-likeness, toxicity and binding affinities using Lipinski’s Rule, PROTox-II and AutoDock 4.2. Binding energies, hydrogen bonds and Van der Waals interactions were analysed.
Results:
All derivatives satisfied Lipinski’s Rule with no violations, demonstrating drug-likeness. Toxicity analysis classified the compounds as non-carcinogenic and non-mutagenic. Binding affinities were highest for 3D (−8.8 kcal/mol) with strong interactions at PRO A: 219, GLY A: 199 and ASN A: 200, forming four hydrogen bonds. Compound 3C (−7.9 kcal/mol) also exhibited significant binding. PABA’s anti-cancer properties and stable protein–ligand interactions highlight its therapeutic potential.
Conclusion:
PABA-substituted pyrimidine derivatives, particularly 3D, show promise as lead compounds for targeting mutant p53 in OSCC. Further in vitro and in vivo studies are warranted to validate their efficacy and safety, paving the way for precision therapies.
SiegelR, MaJ, ZouZ, . Cancer statistics. CA Cancer J Clin, 2014; 64: 9–29.
2.
SungH, FerlayJ, SiegelRL, . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71: 209–249.
3.
TanY, WangZ, XuM, . Oral squamous cell carcinomas: State of the field and emerging directions. Int J Oral Sci, 2023; 15: 44.
4.
RenuK. Lipin-1: Is a promising therapeutic candidate for head and neck cancer. Elsevier, 2024, p.100399.
KumarM, NanavatiR, ModiTG, . Oral cancer: Etiology and risk factors: A review. J Cancer Res Ther, 2016; 12: 458–463.
7.
YiY, TianZ, JuH, . A novel NOTCH3 mutation identified in patients with oral cancer by whole exome sequencing. Int J Mol Med, 2017; 39: 1541–1547.
8.
HassanNMM, TadaM, ShindohM, . A multiple primary carcinoma consisting of leukoplakia and SCC: A case report with p53 mutation analysis. Anticancer Res, 2010; 30: 4773–4778.
9.
KumarRR, KannanB, PandiC, . Dysregulation of a novel m6A regulator YWHAG is correlated with metastasis and poor prognosis in oral squamous cell carcinoma: A cross-sectional study. Arch Oral Biol, 2025; 169: 106090.
10.
EdwardsZC, TrotterEW, Torres-AyusoP, . Survival of head and neck cancer cells relies upon LZK kinase-mediated stabilization of mutant p53. Cancer Res, 2017; 77: 4961–4972.
11.
RamasubramanianA, RamaniP, KannanB, . High expression of novel biomarker TBRG4 promotes the progression and invasion of oral squamous cell carcinoma. J Oral Pathol Med, 2023; 52: 738–745.
12.
GayathriR, RamaniP and VeeraraghavanVP. Longitudinal study on salivary IL-6 trajectories in postoperative OSCC patients after chemotherapy and radiotherapy. J Stomatol Oral Maxillofac Surg, 2024: 125: 101909.
13.
DavidJJ, KannanB, PandiC, . Increased SEC14L2 expression is associated with clinicopathological features and worse prognosis in oral squamous cell carcinoma. Odontology, 2024; 112: 1–9.
14.
PuteriA and MeizariniRA. p53: The guardian of genome against OSCC progression. Eur J Mol Clin Med, 2020; 7: 1071–1079.
StieweT and HaranTE. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance. Drug Resist Updat, 2018; 38: 27–43.
17.
ZhouX, HaoQ and LuH.Mutant p53 in cancer therapy—The barrier or the path. J Mol Cell Biol, 2019; 11: 293–305.
18.
ShahHD, SaranathD and MurthyV.A molecular dynamics and docking study to screen anti-cancer compounds targeting mutated p53. J Biomol Struct Dyn, 2022; 40: 2407–2416.
19.
IslamA, ChangY-C, ChenX-C, . Water-soluble 4-(dimethylaminomethyl) heliomycin exerts greater antitumor effects than parental heliomycin by targeting the tNOX-SIRT1 axis and apoptosis in oral cancer cells. Elife, 2024; 12: RP87873.
20.
ZhaoY, AguilarA, BernardD, . Small-molecule inhibitors of the MDM2–p53 protein–protein interaction (MDM2 inhibitors) in clinical trials for cancer treatment: Miniperspective. J Med Chem, 2015; 58: 1038–1052.
21.
KangY-J, KimD-W, CheX, . Inhibition of TP53 mutant oral cancer by reactivating p53. Appl Sci, 2022; 12: 5921.
22.
RathS, JagadebM and BhuyanR.Molecular docking of bioactive compounds derived from Moringa oleifera with p53 protein in the apoptosis pathway of oral squamous cell carcinoma. Genomics Inform, 2021; 19: e46.
23.
AkberovaS. New biological properties of p-aminobenzoic acid. Biol Bull Russ Acad Sci, 2002; 29: 390–393.
24.
SowinskaM, MorawiakM, Bochyńska-CzyżM, . Molecular antioxidant properties and in vitro cell toxicity of the p-aminobenzoic acid (PABA) functionalized peptide dendrimers. Biomolecules, 2019; 9: 89.
25.
HasanE, AliSN, BanoZ, . An efficient synthesis of O-and N-alkyl derivatives of 4-aminobenzoic acid and evaluation of their anticancer properties. Nat Prod Res, 2024; 38: 2220–2230.
26.
KrátkýM, KonečnáK, JanoušekJ, . 4-Aminobenzoic acid derivatives: Converting folate precursor to antimicrobial and cytotoxic agents. Biomolecules, 2019; 10: 9.
27.
BérubéG and Reyes-MorenoC. Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents. Google Patents, 2022; 6: 100069.
28.
Hamelin-MorrissetteJ, CloutierS, GirouardJ, . Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells. Eur J Med Chem, 2015; 96: 259–268.
29.
OufqirY, FortinL, GirouardJ, . Synthesis of new para-aminobenzoic acid derivatives, in vitro biological evaluation and preclinical validation of DAB-2-28 as a therapeutic option for the treatment of bladder cancer. Eur J Med Chem Rep, 2022; 6: 100069.
30.
GirouardJ, BelgoroskyD, Hamelin-MorrissetteJ, . Molecular therapy with derivatives of amino benzoic acid inhibits tumor growth and metastasis in murine models of bladder cancer through inhibition of TNFα/NFΚB and iNOS/NO pathways. Biochem Pharmacol, 2020; 176: 113778.
31.
NatarajanR, AnthoniSamy HN, SivaperumanA, . Structure-activity relationships of pyrimidine derivatives and their biological activity: A review. Med Chem, 2023; 19: 10–30.
32.
ChoudhuryAAK, VinayagamS, AdhikariN, . Microwave synthesis and antimalarial screening of novel 4-amino benzoic acid (PABA)-substituted pyrimidine derivatives as plasmodium falciparum dihydrofolate reductase inhibitors. 3 Biotech, 2022; 12: 170.
33.
YangH, LouC, SunL, . admetSAR 2.0: Web-service for prediction and optimization of chemical ADMET properties. Bioinformatics, 2019; 35: 1067–1069.
34.
DainaA, MichielinO and ZoeteV. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep, 2017; 7: 42717.
35.
BanerjeeP, EckertAO, SchreyAK, PreissnerR. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res, 2018; 46: W257–W263.
36.
DeLanoWL. Pymol: An open-source molecular graphics tool. CCP4 Newsl Protein Crystallogr, 2002; 40: 82–92.
37.
MorrisGM, HueyR and OlsonAJ. Using autodock for ligand-receptor docking. Curr Protoc Bioinform, 2008; 24: 8.14. 11–18.14;40.
38.
BaughEH, KeH, LevineAJ, . Why are there hotspot mutations in the TP53 gene in human cancers?. Cell Death Differ, 2018; 25: 154–160.
39.
KastenhuberER and LoweSW. Putting p53 in context. Cell, 2017; 170: 1062–1078.
40.
D’OraziG and CironeM.Mutant p53 and cellular stress pathways: A criminal alliance that promotes cancer progression. Cancers, 2019; 11: 614.
41.
TerzianT, SuhY-A, IwakumaT, . The inherent instability of mutant p53 is alleviated by Mdm2 or p16INK4a loss. Genes Dev, 2008; 22: 1337–1344.
42.
JayaramanS, NatarajanSR, VeeraraghavanVP, . Unveiling the anti-cancer mechanisms of calotropin: Insights into cell growth inhibition, cell cycle arrest, and metabolic regulation in human oral squamous carcinoma cells (HSC-3). J Oral Biol Craniofac Res, 2023; 13: 704–713.
43.
SongJ, YuJ, JeongLS, . A novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells. Cancer Lett, 2021; 497: 54–65.
44.
SamalS, MeherRK, DubeyD, . In-silico and in-vitro evaluation of docetaxel and berberine as potential p53 modulating apoptotic inducers in oral squamous cell carcinoma. Asian Pac J Trop Biomed, 2022; 12: 530–540.
45.
PazhaniJ, ChanthuK, JayaramanS, . Evaluation of salivary MMP-9 in oral squamous cell carcinoma and oral leukoplakia using ELISA. J Oral Maxillofac Pathol, 2023; 27: 649–654.
46.
ChenJ. The cell-cycle arrest and apoptotic functions of p53 in tumor initiation and progression. Cold Spring Harb Perspect Med, 2016; 6: a026104.
47.
SelvarajFM, JosephAP, PillaiVR, . Significance of tumour budding and invasive characteristics in grading of oral squamous cell carcinoma. J Oral Maxillofac Pathol, 2023; 27: 642–648.
48.
RuL and ZhengJ.Clinical applications and perspectives of immune checkpoint inhibitors in oral squamous cell carcinoma. Oncologie, 2024; 26: 535–547.
49.
BabikerH, BranaI, MahadevanD, . Phase I trial of cemiplimab, radiotherapy, cyclophosphamide, and granulocyte macrophage colony-stimulating factor in patients with recurrent or metastatic head and neck squamous cell carcinoma. Oncologist, 2021; 26: e1508–e1513.
50.
HuangX, LiuQ, ZhongG, . Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial. J Exp Clin Cancer Res, 2022; 41: 300.
51.
GaoJ, GaoJ, QianL, . Activation of p38-MAPK by CXCL4/CXCR3 axis contributes to p53-dependent intestinal apoptosis initiated by 5-fluorouracil. Cancer Biol Ther, 2014; 15: 982–991.
52.
TongD, PootM, HuD, . 5-Fluorouracil-induced apoptosis in cultured oral cancer cells. Oral Oncol, 2000; 36: 236–241.
53.
HaradaK, FerdousT and UeyamaY.Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes. Int J Oncol, 2014; 44: 1302–1308.
54.
BertkauA, MacDonaldS, RothJ, . Combined effect of para-aminobenzoic acid (PABA) and ionizing radiation in a syngeneic murine model of breast carcinoma. J Clin Oncol, 2004; 22: 3189–3189.
55.
BuckleyM, GittlemanA, DevittM, . Para-aminobenzoic acid (PABA) enhances the anti-tumor activity of radiotherapy (RT) in the human glioblastoma multiforme T98G cell line both in-vitro and in-vivo. Cancer Res, 2007; 67: 3107–3107.
56.
BuckleyMT, NewmanD, LiebesLF, . Para-aminobenzoic acid (PABA) enhances the in-vitro tumor response of ovarian cancer to Topotecan (TTN) through mitochondrial-mediated apoptosis. Cancer Res, 2005; 65: 1258–1258.
57.
PhamT-H, ParkH-M, KimJ, . STAT3 and p53: Dual target for cancer therapy. Biomedicines, 2020; 8: 637.
58.
PoornimaC, AgnihotriP, RajanS, . The role of p53 in oral cancer-a review. J Indian Acad Oral Med Radiol, 2005; 17: 153–156.
59.
ChengY, LiS, GaoL, . The molecular basis and therapeutic aspects of cisplatin resistance in oral squamous cell carcinoma. Front Oncol, 2021; 11: 761379.
60.
MagnanoS, BarroetaPH, DuffyR, . Cisplatin induces autophagy-associated apoptosis in human oral squamous cell carcinoma (OSCC) mediated in part through reactive oxygen species. Toxicol Appl Pharmacol, 2021; 427: 115646.
61.
KhanS, HegdeV, ShrivastavaD, . Comparative assessment of E-cadherin’s expression between the metastatic and non-metastatic oral squamous cell carcinoma: An immunohistochemical study. Pesq Bras Odontopediatria Clín Integr, 2023; 23: e220077.
62.
XavierS, RothJ, CauntM, . Para-amino benzoic acid (PABA) modulates expression and stability of CDC25A in tumor cells and enhances radiosensitivity in vitro and in vivo. Int J Radiat Oncol Biol Phys, 2004; 60: S360–S361.
63.
XavierS, MacDonaldS, RothJ, . The vitamin-like dietary supplement para-aminobenzoic acid enhances the antitumor activity of ionizing radiation. Int J Radiat Oncol Biol Phys, 2006; 65: 517–527.
64.
HaroonF, FarwaU, ArifM, . Novel para-aminobenzoic acid analogs and their potential therapeutic applications. Biomedicines, 2023; 11: 2686.
65.
LipinskiCA. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov Today Technol, 2004; 1: 337–341.
66.
HientzK, MohrA, Bhakta-GuhaD, . The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget, 2017; 8: 8921–8946.
67.
ShenH and G MakiC. Pharmacologic activation of p53 by small-molecule MDM2 antagonists. Curr Pharm Des, 2011; 17: 560–568.
WiegeringA, MatthesN, MühlingB, . Reactivating p53 and inducing tumor apoptosis (RITA) enhances the response of RITA-sensitive colorectal cancer cells to chemotherapeutic agents 5-fluorouracil and oxaliplatin. Neoplasia, 2017; 19: 301–309.
70.
TangX, ZhuY, HanL, . CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Investig, 2007; 117: 3753–3764.
71.
LambertJM, GorzovP, VeprintsevDB, . PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell, 2009; 15: 376–388.
72.
SinghS, GuptaH, SharmaP, . Advances in artificial intelligence (AI)-assisted approaches in drug screening. Artif Intell Chem, 2024; 2: 100039.
73.
KokudevaM, VichevM, NasevaE, . Artificial intelligence as a tool in drug discovery and development. World J Exp Med, 2024; 14: 96042.
74.
GentileF, YaacoubJC, GleaveJ, . Artificial intelligence–enabled virtual screening of ultra-large chemical libraries with deep docking. Nat Protoc, 2022; 17: 672–697.
